Product
MID Prism (AI-Powered Diagnostics)
High-precision detection of antibody changes, capable of identifying Mycoplasma infections even in asymptomatic patients.
Author
CEO & Founder at M Bio Technology Inc.
TOKYO, Japan
About
M Bio Technology Inc.: Unlocking the Frontier of Neuroimmune Medicine
M Bio Technology is a Tokyo-based biotechnology pioneer dedicated to tackling one of the most overlooked global health threats: Mycoplasma-driven neuroimmune diseases. While Mycoplasma is often associated with pediatric pneumonia—linked to up to 50% of cases—its role as a trigger for severe autoimmune and neurological conditions remains largely undiagnosed and untreated.
We are building a Japan-originated global clinical trial hub to transform how the world diagnoses, treats, and prevents these conditions, which include acute disseminated encephalomyelitis (ADEM), multiple sclerosis (MS), and various psychiatric disorders.
Areas of activity
CL 4: Quantum
HORIZON-CL4-2026-04-DIGITAL-EMERGING-11: Grand Challenge on Quantum Sensors for Inertial Navigation
CL 4: Other emerging technologies
HORIZON-CL4-2027-04-DIGITAL-EMERGING-10: Horizon scanning and foresight in future enabling digital technologies (CSA)
CL 4: Virtual Worlds – Web 4.0 (Partnership)
HORIZON-CL4-2026-04-HUMAN-01: Developing and demonstrating core technologies for Virtual Worlds and Web 4.0 (IA) (Virtual worlds Partnership)
CL 6: Innovating for sustainable bio-based systems, biotechnology and the bioeconomy
HORIZON-CL6-2026-01-CIRCBIO-07: Advancing the European bio-based innovation enabled by biotechnology and biomanufacturing conceptsHORIZON-CL6-2027-01-CIRCBIO-08: Biotechnology application for CCU
CL4: Sustainable Advanced Materials, Raw Materials and Chemicals
HORIZON-CL4-2027-01-MATERIALS-PRODUCTION-22: Innovative advanced materials and new production processes – reducing dependencies on Critical and Strategic Raw Materials (IA) (Innovative Advanced Materials for the EU and Processes4Planet partnerships)HORIZON-CL4-2026-01-MATERIALS-PRODUCTION-24: Cooperation on innovative advanced materials with Japan (CSA)
CL 4: Technology infrastructure, knowledge valorisation and support for scaleups and startups
HORIZON-CL4-2027-01-MATERIALS-PRODUCTION-42: Unlocking the potential of academic intellectual assets for industry, SMEs and startups (CSA)HORIZON-CL4-2027-01-MATERIALS-PRODUCTION-61: Fast Track to Research and Innovation for breakthroughs in industrial technologies (Research and Innovation Action)
CL 4: AI for manufacturing and energy-intensive industries
HORIZON-CL4-2027-02-DIGITAL-EMERGING-52: New approaches for Human/AI collaboration for the workforce of the future (RIA) (Made in Europe and AI, Data and Robotics partnerships)
Representatives
Remote
Remote
CEO & Founder
M Bio Technology Inc.
Marketplace (5)
Product
MID Modality (Vaccine Innovation)
The world’s first synthetic glycolipid antigen-based vaccines, designed for high purity and global scalability.
AuthorCEO & Founder at M Bio Technology Inc.
TOKYO, Japan
Product
MID Navigator (Digital Health/Clinical Trials)
A PMDA-compliant trial orchestration tool and digital care system to guide physicians with real-time insights.
AuthorCEO & Founder at M Bio Technology Inc.
TOKYO, Japan
Project cooperation
Ongoing negotiations with a Global Tier-1 Vaccine Pharma and established partnerships with top-tier European CDMOs for GMP manufacturing.
AuthorCEO & Founder at M Bio Technology Inc.
TOKYO, Japan
Expertise
Deep domain knowledge in rare neuroimmune diseases like ADEM and Multiple Sclerosis (MS) triggered by infections.
AuthorCEO & Founder at M Bio Technology Inc.
TOKYO, Japan